Details

NameSymbolSector
CIPLA LTD.CIPLAPharmaceuticals
Open
1372.2
High
1385.9
Low
1303
Close
1315
Volume
6590032
Exchange
nse
Time
23-Jan-2026

Outlook

Score:  

1.75

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Cipla is  
Long Body
Estimated Stoploss of Cipla is ₹  
1385.9
Cipla has a  
Bearishℹ
 pattern. 
Formation of  
Long Body
 candle pattern indicates Cipla has chances of  
Continuationℹ
 of the current trend. 

Trend

Cipla is in  
Downtrendℹ
. 
Price of Cipla is  
Downℹ
 by  

10.82

%. 
Target
Buy @ 

1303

Sell @ 

1516

Current @ 

1315

Volume

The trades of Cipla have been in  
Immenseℹ
 volume. 
The volume trades for Cipla are  
Bearishℹ
 with  
Strong Sellersℹ
The trade volume of Cipla is  

Up

 by  

327.62

% 

Valuation

The current market price of Cipla is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 37387cr and total assets worth ₹ 37387cr, the balance sheet of Cipla is:  
Balancedℹ
. 
Cashflow
Cipla has  
Maintainedℹ
 cash flow because there is  

Surplus

 of  

₹ 30cr

. It is  
Upℹ
 by  

162.5

%. 

(*Mar 2025)

50.06% i.e. ₹ 5004cr earned in operatingℹ
36.92% i.e. ₹ 3691cr spent in investingℹ
12.93% i.e. ₹ 1292cr spent in financingℹ
0.09% i.e. ₹ 9cr earned in otherℹ
Cipla has  
Poorℹ
 cash flow because there is  

Shortage

 of  

₹ 48cr

. It is  
Upℹ
 by  

50

%. 

(*Mar 2024)

49.64% i.e. ₹ 4133cr earned in operatingℹ
35.89% i.e. ₹ 2988cr spent in investingℹ
14.41% i.e. ₹ 1200cr spent in financingℹ
0.06% i.e. ₹ 5cr earned in otherℹ
Income
The income of Cipla is  

₹ 7858cr

 and  

Profit

 is :  

₹ 1353cr

(*Sep 2025)

Cipla Profit is up by:  

4.72

% and Income is Up by:  

8.9

% 

(*Sep 2025)

The income of Cipla is  

₹ 7216cr

 and  

Profit

 is :  

₹ 1292cr

(*Jun 2025)

Cipla Profit is up by:  

5.47

% and Income is Up by:  

2.81

% 

(*Jun 2025)

The income of Cipla is  

₹ 7019cr

 and  

Profit

 is :  

₹ 1225cr

(*Mar 2025)

Cipla Profit is down by:  

22.62

% and Income is Down by:  

3.77

% 

(*Mar 2025)

By using this site you agree to the use of cookies to deliver a better site experience.